Identification of Key Methylation Differentially Expressed Genes in Posterior Fossa Ependymoma Based on Epigenomic and Transcriptome Analysis

Guanyi Wang
  Xijing Hospital Department of neurosurgery  https://orcid.org/0000-0003-1202-4651

Yibin Jia
  Department of Neurosurgery, Xijing Hospital, Airforce Military Medical Medical University (Fourth Military Medical University), Xi’an 710032, China

Yuqing Ye
  Department of Neurosurgery, Xijing Hospital, Airforce Military Medical Medical University (Fourth Military Medical University), Xi’an 710032, China. Department of Neurosurgery, PLA 163rd Hospital (Second Affiliated Hospital of Hunan Normal University), Changsha 41

Enming Kang
  Department of Neurosurgery, Xijing Hospital, Airforce Military Medical Medical University (Fourth Military Medical University), Xi’an 710032, China

Huijun Chen
  Department of Neurosurgery, Xijing Hospital, Airforce Military Medical Medical University (Fourth Military Medical University), Xi’an 710032, China

Jiayou Wang
  Department of Neurosurgery, Xijing Hospital, Airforce Military Medical Medical University (Fourth Military Medical University), Xi’an 710032, China

Xiaosheng He (hexiaos@fmmu.edu.cn)
  Department of Neurosurgery, Xijing Hospital, Airforce Military Medical Medical University (Fourth Military Medical University), Xi’an 710032, China

---

Research

Keywords: posterior fossa ependymoma, epigenome, transcriptome, differential genes, WGCNA

DOI: https://doi.org/10.21203/rs.3.rs-148618/v1

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

Read Full License
Abstract

Background

Posterior fossa ependymoma (EPN-PF) can be classified into Group A posterior fossa ependymoma (EPN-PFA) and Group B posterior fossa ependymoma (EPN-PFB) according to DNA CpG island methylation profile status and gene expression. EPN-PFA usually occurs in children younger than 5 years and has a poor prognosis.

Methods

Using epigenome and transcriptome microarray data, a multi-component weighted gene co-expression network analysis (WGCNA) was used to systematically identify the hub genes of EPN-PF. We downloaded two microarray datasets (GSE66354 and GSE114523) from the Gene Expression Omnibus (GEO) database. The Limma R package was used to identify differentially expressed genes (DEGs), and ChAMP R was used to analyze the differential methylation genes (DMGs) between EPN-PFA and EPN-PFB. GO and KEGG enrichment analyses were performed using the Metascape database.

Results

GO analysis showed that enriched genes were significantly enriched in the extracellular matrix organization, adaptive immune response, membrane raft, focal adhesion, NF-kappa B pathway, and axon guidance, as suggested by KEGG analysis. Through WGCNA, we found that MEblue had a significant correlation with EPN-PF ($R=0.69, P=1 \times 10^{-08}$) and selected the 180 hub genes in the blue module. By comparing the DEGs, DMGs, and hub genes in the co-expression network, we identified five hypermethylated, lower expressed genes in EPN-PFA (ATP4B, CCDC151, DMKN, SCN4B, and TUBA4B), and three of them were confirmed by IHC.

Conclusion

ssGSEA and GSVA analysis indicated that these five hub genes could lead to poor prognosis by inducing hypoxia, PI3K-Akt-mTOR, and TNFα-NFKB pathways. Further study of these dysmethylated hub genes in EPN-PF and the pathways they participate in may provides new ideas for EPN-PF treatment.

1. Introduction

Ependymoma (EPN) is a rare neuroepithelial tumor that occurs in both adults and children. As the third most common central nervous system tumor in children, it accounts for 10% of primary intracranial tumors in children, and two-thirds of the tumors are located in the posterior fossa (PF)\(^1\text{-}^2\). Based on histopathological criteria, the World Health Organization (WHO) classifies ependymomas as grades II and III tumors. However, whether this classification has guiding significance for prognosis has been controversial. Recently, according to the DNA CpG island methylation profile status and gene expression,
posterior fossa ependymoma (EPN-PF) has been classified into two subtypes: Group A, posterior fossa ependymoma (EPN-PFA), and Group B, posterior fossa ependymoma (EPN-PFB)\(^3\).

Compared to EPN-PFB, EPN-PFA exhibits CpG hypermethylation, H3K27me3 reduction, global DNA hypomethylation, and EZHIP expression \(^4\text{–}^7\). Clinical observations reveal that EPN-PFA usually occurs in children younger than 5 years and has a poor prognosis. Conversely, EPN-PFB usually occurs in children and adults older than five years, and the prognosis is relatively good\(^3\), \(^8\text{–}^9\). At present, more in-depth studies are available about H3K27me3 and its mechanism of deletion. With the discovery of EZHIP, trials of various targeted drugs, such as the DNA methylation inhibitor decitabine\(^9\text{–}^10\), selective EZH2 inhibitor GSK343, histone deacetylase inhibitor (HDACi) SAHA\(^11\), have been initiated\(^4\), \(^12\).

To date, there are few studies about gene level targets. To the best of our knowledge, our study is the first to perform multi-omic weighted gene co-expression network analysis (WGCNA) to identify the hub genes of EPN-PF using both transcriptome- and epigenome-wide microarray data. The purpose of this study was to identify the differential hub genes between EPN-PFA and EPN-PFB and to explore their influence on prognosis from immunity and the pathways they participate.

2. Methods

2.1 Datasets

We downloaded two microarray datasets from the Gene Expression Omnibus (GEO) database. The dataset (GSE66354)\(^13\) included gene expression profiles from surgical tumor and normal brain samples \((n = 149)\) using Affymetrix HG-U133plus2 chips (Platform GPL570). We obtained the gene expression profiles of EPN-PFA \((n = 29)\) and EPN-PFB \((n = 26)\) from the dataset. In addition, we obtained DNA methylation profiles from 43 EPN-PFA and 12 EPN-PFB patients from the data set (GSE114523)\(^14\). The workflow of this study is shown in Fig. 1.

2.2 Combined analysis of DNA methylation and transcriptome

DNA methylation causes transcriptional silencing to regulate gene expression. EPN-PF was also divided into two subtypes according to the level of CpG island methylation, and the prognosis was significantly different\(^15\). Therefore, we used GSE66354 and GSE114523 to find the hub-methylated genes.

The Limma R package was used to identify differentially expressed genes (DEGs), and the differential expression threshold was \(|\log FC| > 1 & P < 0.05\). We used the ChAMP R package to analyze the differential methylation genes (DMGs). The screening conditions were as follows: the \(\beta\) value of one group should be less than 0.2, whereas the other group should be greater than 0.3 and adjusted to \(P < 0.05\). Next, we identified the EPN-PF-related DMGs, including hypomethylated, highly expressed genes (Hypo-HGs) and hypermethylated, low expressed genes (Hyper-LGs).
Lastly, the Metascape database ([www.metascape.org](http://www.metascape.org))[^16] was used for functional and pathway enrichment analyses, Gene Ontology (GO) analysis, and Kyoto Genome Encyclopedia (KEGG) pathway analysis. Protein-protein interaction (PPI) network was carried out for the genes we obtained above. A Min overlap ≥ 3 & P ≤ 0.01 was considered statistically significant.

### 2.3 Weighted gene co-expression network construction

We used the raw microarray data from GSE66354 to construct the gene co-expression networks using the WGCNA package[^17]. By constructing a weighted gene co-expression network, we can find the gene modules of co-expression, and explore the relationship between gene network and phenotype as well as the core genes in the network. A matrix of similarity was constructed by calculating the correlations of all pairs of genes, then we ranked them by variance size and screened the top 5000 genes for the next analysis. The missing values were filled using the Impute package. The correlation between genes was calculated by the Pearson correlation matrix and the means of the connecting rod. An appropriate soft-thresholding power β was selected by using the integrated function (pickSoftThreshold) in the WGCNA package; here, the soft thresholding power is 9. The weighted adjacency matrix was transformed into a topological overlap degree matrix (TOM) to estimate the network connectivity, and the hierarchical clustering method was used to construct the clustering tree structure of the TOM matrix[^18]. Different branches of the clustering tree represent different gene modules, and different colors represent different modules. Based on the weighted correlation coefficient of genes, genes are classified according to expression patterns, and genes with similar patterns are grouped into one module, whereas tens of thousands of genes are grouped into multiple modules through gene expression patterns[^19].

### 2.4 Identification of hub modules and hub genes

To identify the hub modules, we performed principal component analysis for module eigengenes (ME) and evaluated the Pearson correlation analysis between MEs and phenotype of EPN-PF. The most significant correlation modules were identified as hub modules. Subsequently, the genes within such modules were matched with EPN-PF-related DMGs to identify EPN-PF-related hub DMGs.

### 2.5 Subjects and specimen collection

Between July 2017 and June 2020, we obtained six pairs of EPN-PF tissues from 12 patients at the Department of Neurosurgery, Xijing Hospital, Air Force Military Medical University. After surgery, the tumor tissue was preserved at 80 °C until use. This study was approved by the ethics committee of Xijing Hospital and the number is KY20202060-F-1.

### 2.6 Immunohistochemistry

To determine the pathological subtype of each tumor, tumor sections were processed for immunostaining with antibodies against H3K27me3 (Rabbit, ThermoFisher, PA5-31817, 1:100). The cases with global reduction of H3K27me3 were considered EPN-PFA; in contrast, cases with H3K27me3 nuclear immunopositivity to be EPN-PFB. Then, in order to verify the expression level of the hub genes in two subtypes of EPN-PF, we immunostained the tumor sections with antibodies against ATP4B(Mouse,
Invitrogen, MA3-923, 1:2000), CCDC151(Rabbit, ThermoFisher, PA5-62991, 1:1000), DMKN(Rabbit, Abcam, ab246965, 1:200), and SCN4B(Rabbit, Abcam, ab219816, 1:100).

The tumor tissue was immersed in 4% paraformaldehyde at 4 °C overnight, dehydrated with alcohol, and embedded in paraffin. Then, 5 µm thick sections were prepared using a microtome (Leica, Nussloch, Germany) and dried overnight at 94 °C. We selected 10 sections from each tissue and deparaffinized the sections using alcohol and dimethylbenzene. We then incubated the sections in citric acid antigen recovery buffer (pH = 6.0) at 95 °C for 10 min. Next, we incubated the sections in phosphate buffer saline (PBS) with 1% donkey serum albumin and 0.3% Triton X-100 at 25 °C for 30 min. After preparation, the sections were dewaxed with xylene and rehydrated with a reduced alcohol solution. The sections were immersed in citrate buffer solution (pH 6.0), heated at high temperature in a microwave oven for 8 min, then taken out and cooled to room temperature and washed with PBS. Endogenous peroxide activity was quenched with 3% hydrogen peroxide for 15 min. Sheep serum (5%) was added to the slices and placed in a wet box at room temperature for 20 min and washed with PBS. The sections were first incubated with the primary antibodies mentioned above in PBS at 4 °C overnight. After washing, the tumor sections were treated with the corresponding secondary antibodies for 1 h at room temperature, and further incubated with HRP-labeled streptavidin. After washing, we added 50–100 µL of 3,3′-Diaminobenzidine (DAB) working solution to the sections. After color development, the sections were washed in distilled water, soaked in hematoxylin for 1–3 min, washed with distilled water, and then turned blue with PBS. Lastly, we dehyrdate, transparent, and covered the sections and then examined them under a microscope.

The sections were evaluated using the AxioVision Rel.4.6 computerized image analysis system assisted by an automatic measurement program (Nikon). The mean absorbance of the sections was determined as a measure of the strength of staining signals, as measured per positive pixel. The data were analyzed by t-test, all statistical analyses were conducted using GraphPad Prism 7 and \( P < 0.05 \) was considered statistically significant. Thus, we evaluated the expression of hub genes in different subtypes.

### 2.7 Functional enrichment analysis

The single-sample gene set enrichment (ssGSEA) algorithm was performed based on the specific marker gene expression information of immune cells \[^{[20]}\]; here, we used it to quantify the abundance of each tumor microenvironment (TME) cell infiltration. The adjusted enrichment scores calculated by ssGSEA analyses were used to represent the abundance of each TME infiltration cell. We evaluated 28 human TME cell subtypes, including B cells, CD8 + T cells, T helper cells, CCR, pDCs, and Th1 cells. The immune infiltration patterns and antigen-presenting activation levels were represented by the ssGSEA score. Then, the EPN-PF-related hub DMGs were analyzed via ssGSEA and gene set variation analysis (GSVA) \[^{[21]}\] algorithm to comprehensively score each gene set to evaluate the potential biological function changes of different samples. \( P < 0.05 \), gene size greater than or equal to 15 and enrichment score (ES) > 0.3 were set as the cut-off value.

### 3. Results
3.1 Identification of EPN-PF-related DMGs.

By analyzing the GSE66354 dataset, we found that 649 genes were upregulated and 542 genes were downregulated in all 1191 DEGs between the two EPN-PF subtypes. The top 10 up- and down-regulated DEGs are provided in Fig. 2A and B. In the methylation profiling dataset of GSE114523, we found 1790 hypermethylated genes and 1101 hypomethylated genes (Fig. 2C). Then, using a Venn diagram, 83 Hypo-HGs and 63 Hyper-LGs were revealed (Fig. 2D and E). Collectively, 146 aberrantly methylated DEGs were identified as EPN-PF-related DMGs.

3.2 GO term, KEGG pathway, and PPI analysis

To further investigate the biological functions and signaling pathways involved in the occurrence and development of diseases, we analyzed both Hypo-HGs and Hyper-LGs through GO, KEGG, and PPI analyses. The significant GO terms and KEGG pathway are shown in Fig. 3A and C. As shown in the GO analysis, the EPN-PF-related DMGs were remarkably enriched in extracellular matrix organization, adaptive immune response, and membrane raft. Furthermore, we found that the focal adhesion, NF-kappa B pathway, and axon guidance were significantly enriched as suggested by KEGG analysis. Through the PPI network analysis, we obtained two significant modules, which are shown in Fig. 3B and D.

3.3 WGCNA and identification of hub modules

As shown in Fig. 4A, sample clustering revealed that sample GSM1620246 required removal from subsequent analysis due to outliers. Subsequently, we included the remaining 54 samples in the WGCNA analysis and identified nine modules on the thresholding power of $\beta = 9$ (Fig. 4B-D). Combined with the module and clinical information, we ultimately identified the blue module, which contains 805 genes and was highly correlated with EPN-PF ($R = 0.69, p = 1E-08$, Fig. 4E). We then selected the 180 hub genes in the blue module (Fig. 4F).

3.4 Identification of EPN-PF-related hub DMGs

Through the screening above, we compared the EPN-PF-related DMGs and the hub genes we obtained in WGCNA, and identified five genes as EPN-PF-related hub DMGs: ATP4B, CCDC151, DMKN, SCN4B, and TUBA4B (Fig. 5A-G).

3.5 Verification of EPN-PF-related hub DMGs expression by IHC

Using an IHC assay to detect the expression levels of the hub DMGs obtained above, we verified the reliability of the bioinformatics analysis results. First, we identified the subtypes of the tumors we obtained (Fig. 6). As shown in Fig. 7, ATP4B, CCDC151, DMKN, and SCN4B levels were decreased in EPN-PFA compared with EPN-PFB, which was consistent with the predictions. Except for SCN4B ($P = 0.1579$), the differences in the other three were statistically significant ($P<0.05$).

3.6 Functional enrichment analysis
To explore the roles of key molecules identified in the TME immune cell infiltration, we evaluated the landscape of 28 TME cell infiltration in two subtypes of EPN-PF samples. As shown in Fig. 8A, there were remarkably differences in immune cells between the two subtypes. To further explore the relationship between the five EPN-PF-related hub DMGs and the infiltration of immune cells, we conducted the ssGSEA algorithm to estimate the coefficient of the association of five genes in the immune cell subsets. We found that the expression levels of these five genes were highly related to the abundance of multiple immune cells (Fig. 8B).

Next, we used GSVA to determine the pathways enriched in these five genes. Among the abundant pathways involved in the five genes, we found several overlapping and significantly different pathways related to tumorigenesis, development, and prognosis: PI3K-Akt-mTOR, TNFα-NFKB, and hypoxia (Fig. 9A-E)

4. Discussion

The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) recently recognized the classification of EPN-PF into two subtypes, according to their methylation levels[22]. The occurrence of tumors is often accompanied by an imbalance in DNA methylation and inactivation of tumor suppressor genes by abnormal methylation is particularly important[23]. Since EPN-PFA is more likely to occur in children under 5 years of age and has a poor prognosis, most of the studies previously conducted have focused on its molecular biological characteristics, namely the deletion mechanism of H3K27me3.

In the present study, we first identified key differential genes between EPN-PFA and EPN-PFB by performing a combined analysis of transcriptome, methylation, and WGCNA, and then analyzed the relationship between the key differential genes and immune pathways in an attempt to explore the role and influence of immune-related pathways in prognosis. Through a multi-omic analysis using expression profiles and methylation profiles, EPN-PF-related DMGs were identified by merging Hypo-HGs and Hyper-LGs together. GO, KEGG, and PPI analyses showed that these DMGs are closely related to the occurrence and development of tumors and immune response pathways such as extracellular matrix organization, neuroinflammatory response, and NF-kappa B signaling pathway.

We then performed a multi-omic WGCNA to systematically identify modules related to EPN-PF based on expression pattern similarities in the 54 samples. In the blue module, which contained 805 genes, we selected 180 hub genes related to EPN-PF. Comparing these genes and the EPN-PF-related DMGs obtained above, we identified five EPN-PF-related hub DMGs: ATP4B, CCDC151, DMKN, SCN4B, and TUBA4B. All of the five genes were highly expressed in EPN-PFB and were less expressed in EPN-PFA. We verified that ATP4B, CCDC151, DMKN, and SCN4B levels were decreased in EPN-PFA compared with EPN-PFB, which was consistent with the predictions. However, perhaps due to the limitation of sample size, the difference in SCN4B was not statistically significant.
The role of these five genes in EPN-PF has never been investigated. The gastric H+K+-ATPase (ATP4) is a dimeric heterodimer composed of two catalytic α-subunits and two regulatory β-subunits. The β-subunits were coded using ATP4B genes[24]. Many studies have revealed that ATP4B expression is decreased in human gastric cancer (GC)[25–28], and some studies have reported abnormal expression of ATP4B in other diseases such as human hepatocellular carcinoma (HCC)[29], laryngopharyngeal reflux, and laryngeal cancer[30]. However, to date, there are no studies about the relationship between this gene and EPN-PF. Similar to the EPN-PF, the ATP4B expression was decreased in GC associated with DNA hypermethylation[31]. A study reported that ATP4B could affect part of nerve function through the immune pathway, and then affect the mental state[32], prompting that ATP4B may affect the prognosis of patients by affecting mental health and immune function.

The CCDC151 gene encodes a coiled-coil protein critical for ODA-complex assembly. Several studies have shown that CCDC151 nonsense mutations can cause primary ciliary dyskinesia (PCD), a complex disease caused by structural or developmental defects that hinder the normal movement of cilia[33–35]. In many organs and systems of humans and mice, movable cilia play a key role in the flow of physiological fluids along the epithelial surface, and in the nervous system, cilia are essential for the normal flow of cerebrospinal fluid (CSF) into the central canal of the spinal cord[36–37]. A recent study showed that functional loss of CCDC151 could lead to hydrocephalus in a mouse model of primary ciliary dyskinesia[38]. Therefore, the low expression of CCDC151 may affect the prognosis of EPN-PFA children by casing hydrocephalus.

The DMKN gene is located on human chromosome 19q13.12 and encodes 10 putative dermokine (DMKN) transcriptional subtypes in normal epidermis[39]. Studies have confirmed that the abnormal expression of DMKN is related to skin cancer[40], pancreatic cancer[41], colorectal cancer[42], and other cancers, but no study has shown its role in nervous system tumors. However, a report showing that DMKN can affect the activation of STAT3 and down-stream molecular proteins of the MAPK and PI3K signaling pathways suggests that DMKN may play a role in nervous system tumors through this pathway[41].

Sodium voltage-gated channel beta subunit 4 (SCN4B), one of the β-subunits of the sodium channel, regulates the channel gated dynamics and causes voltage-dependent negative shifts in the activation of some α-sodium channels[43]. The variants in SCN4B have been shown to be associated with ventricular tachyacrdia[44], Huntington’s disease[45], and can be a new biomarker of aggressive cancers[45]. Moreover, Marin et al. showed that SCN4B has a very high interconnection and participation in febrile seizures, nervous disorders, neuromuscular and neurodegenerative diseases, and neurobehavioral manifestations[47]. Therefore, we can boldly speculate that SCN4B is related to EPN-PF. Similar to SCN4B, the low expression of Tubulin alpha 4b (TUBA4B) has also been shown to be significantly associated with poor prognosis of cancer patients[48].
In a variety of human cancers, there is increasing evidence that immunobiology plays an important role in tumor eradication or promotion. The interaction of immunobiological factors in central nervous system malignant tumors has been widely studied\[49–52\]. Some studies have also confirmed that immunity in EPN-PF plays a role\[53–54\], but the number and depth of research is far from enough. Therefore, we conducted the ssGSEA and GSVA algorithms to explore the possible role of EPN-PF-related hub DMGs in the immune system. Through the ssGSEA analysis, we clearly demonstrated that the EPN-PFA and EPN-PFB have significant differences in immunological characteristics, which is consistent with previous studies\[54\]. Our GSVA analysis showed three crucial pathways related to these five hub genes: PI3K-Akt-mTOR, TNFα-NFKB, and hypoxia.

In a recent study, Michealraj et al. showed that the hypoxic microenvironment is essential for the propagation and growth of EPN-PFA and is associated with poor prognosis\[55\]. In our study, all five hub genes were connected with hypoxia and confirmed previous research from some aspects. Other enriched biological pathways, such as the PI3K-Akt signaling pathway and extracellular matrix organization, were also closely related to tumor progression and hypoxic microenvironment formation. Moreover, the hypoxic microenvironment could affect the metabolism of tumor cell, induce adaptive changes in cell metabolism, and regulate complex cell signaling pathways, such as NFKB, which participates in inflammatory response and regulates cell proliferation and survival\[56–57\].

### 5. Conclusion

In conclusion, we performed a combined analysis of transcriptome, methylation, and WGCNA and identified five novel hypermethylated genes, that were less expressed in EPN-PFA as EPN-PF-related hub genes (ATP4B, CCDC151, DMKN, SCN4B, and TUBA4B), and three of them were confirmed by IHC. Further analysis revealed that these five hub genes could lead to poor prognosis by inducing hypoxia, PI3K-Akt-mTOR, and TNFα-NFKB pathways. Further study of these dysmethylated hub genes in EPN-PF and the pathways they participate in may provides new ideas for EPN-PF treatment.

The findings of this study must be seen in light of some limitations. First, the antibody for TUBA4B was not found; therefore, we did not verify the reliability of its expression difference. Second, due to the limitation of the sample size, we could not verify the differences in SCN4B. Lastly, as our tumor tissues were limited, and some of them were made into paraffin sections, IHC was performed instead of RT-qPCR to verify the expression difference. In the follow-up experiment, we will collect fresh tumor samples for testing to compensate for the limitations of this trial.

### Abbreviations

- Posterior fossa ependymoma (EPN-PF)
- weighted gene co-expression network analysis (WGCNA)
Gene Expression Omnibus (GEO)
differentially expressed genes (DEGs)
differential methylation genes (DMGs)
Ependymoma (EPN)
Kyoto Genome Encyclopedia (KEGG) pathway analysis
Protein-protein interaction (PPI)
Gene Ontology (GO)
World Health Organization (WHO)
3,3'-Diaminobenzidine(DAB)
phosphate buffer saline (PBS)

Declarations

Funding

The present work was supported by the Natural Science Foundation of China (NSFC) grant to Xiaosheng He (Nos. 81971156 and 2020XC015).

Author Contributions

GW had the idea for the article; GW, YJ designed the experiments; GW, YJ, and EK carried out the experiments. GW and HC analyzed the data and experimental results. The manuscript was written by GW and YY. YJ and JW critically revised the work. All authors have read and approved the final manuscript.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

The collection of the patient samples, the isolation of tumor cells, and the analysis of the obtained samples was approved by the ethics committee of Xijing Hospital (KY20202060-F-1). Our study adhere to the tenets of the 1964 Declaration of Helsinki. All studies obtained informed sympathy from patients.

Consent for publication
Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgements**

Not applicable.

**References**

1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015, 17 Suppl 4: v1-v62.
2. Gerstner ER, Pajtler KW. Ependymoma. Semin Neurol. 2018, 38(1): 104-111.
3. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015, 27(5): 728-743.
4. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014, 506(7489): 445-450.
5. Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol. 2017, 134(5): 705-714.
6. Bayliss J, Mukherjee P, Lu C, Jain SU, Chung C, Martinez D, et al. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med. 2016, 8(366): 161r-366r.
7. Jain SU, Do TJ, Lund PJ, Rashoff AQ, Diehl KL, Cieslik M, et al. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nat Commun. 2019, 10(1): 2146.
8. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011, 20(2): 143-157.
9. P W. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J Stem Cells. 2015, 7(1): 137-148.
10. Sandberg DI, Yu B, Patel R, Hagan J, Miesner E, Sabin J, et al. Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. J Neurooncol. 2019, 141(2): 449-457.
11. Rahman R, Osteso-Ibanez T, Hirst RA, Levesley J, Kilday JP, Quinn S, et al. Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. Mol Cancer Ther. 2010, 9(9): 2568-2581.
12. Rogers HA, Chapman R, Kings H, Allard J, Barron-Hastings J, Pajtler KW, et al. Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. Oncotarget. 2018, 9(92): 36530-36541.

13. Griesinger AM, Josephson RJ, Donson AM, Mulcahy LJ, Amani V, Birks DK, et al. Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. Cancer Immunol Res. 2015, 3(10): 1165-1174.

14. Fukuoka K, Kanemura Y, Shofuda T, Fukushima S, Yamashita S, Narushima D, et al. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun. 2018, 6(1): 134.

15. Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, et al. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol. 2016, 34(21): 2468-2477.

16. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019, 10(1): 1523.

17. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. Bmc Bioinformatics. 2008, 9: 559.

18. Botia JA, Vandrovocova J, Forabosco P, Guelfi S, D'Sa K, Hardy J, et al. An additional k-means clustering step improves the biological features of WGCNA gene co-expression networks. Bmc Syst Biol. 2017, 11(1): 47.

19. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabasi AL. Hierarchical organization of modularity in metabolic networks. Science. 2002, 297(5586): 1551-1555.

20. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013, 39(4): 782-795.

21. Hanzelmann S, Castelo R, Gunney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC BIOINFORMATICS 2013, 14: 7.

22. Ellison DW, Aldape KD, Capper D, Fouladi M, Gilbert MR, Gilbertson RJ, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. BRAIN Pathol. 2020.

23. Zhang MW, Fujiwara K, Che X, Zheng S, Zheng L. DNA methylation in the tumor microenvironment. J Zhejiang Univ Sci B. 2017, 18(5): 365-372.

24. Gumz ML, Lynch IJ, Greenlee MM, Cain BD, Wingo CS. The renal H+K+-ATPases: physiology, regulation, and structure. Am J Physiol Renal Physiol. 2010, 298(1): F12-F21.

25. Wang G, Hu N, Yang HH, Wang L, Su H, Wang C, et al. Comparison of global gene expression of gastric cardia and noncardia cancers from a high-risk population in china. Plos One. 2013, 8(5): e63826.

26. Yan Z, Luke BT, Tsang SX, Xing R, Pan Y, Liu Y, et al. Identification of gene signatures used to recognize biological characteristics of gastric cancer upon gene expression data. Biomark Insights.
27. Wang W, He Y, Zhao Q, Zhao X, Li Z. Identification of potential key genes in gastric cancer using bioinformatics analysis. Biomed Rep. 2020, 12(4): 178-192.

28. Ray AM, Zunic A, Alten RL, McElfresh JS, Hanks LM, Millar JG. Cis-Vaccenyl acetate, a female-produced sex pheromone component of Ortholeptura valida, a longhorned beetle in the subfamily Lepturinae. J Chem Ecol. 2011, 37(2): 173-178.

29. Shao RX, Hoshida Y, Otsuka M, Kato N, Tateishi R, Teratani T, et al. Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. World J Gastroenterol. 2005, 11(13): 1995-1999.

30. McCormick CA, Samuels TL, Battle MA, Frolkis T, Blumin JH, Bock JM, et al. H+/K+ATPase Expression in the Larynx of Laryngopharyngeal Reflux and Laryngeal Cancer Patients. Laryngoscope. 2020.

31. Lin S, Lin B, Wang X, Pan Y, Xu Q, He JS, et al. Silencing of ATP4B of ATPase H(+)/K(+) Transporting Beta Subunit by Intragenic Epigenetic Alteration in Human Gastric Cancer Cells. Oncol Res. 2017, 25(3): 317-329.

32. Ching KH, Burbelo PD, Carlson PJ, Drevets WC, Iadarola MJ. High levels of Anti-GAD65 and Anti-Ro52 autoantibodies in a patient with major depressive disorder showing psychomotor disturbance. J Neuroimmunol. 2010, 222(1-2): 87-89.

33. Hjeij R, Onoufriadis A, Watson CM, Slagle CE, Klena NT, Dougherty GW, et al. CCDC151 mutations cause primary ciliary dyskinesia by disruption of the outer dynein arm docking complex formation. AM J Hum Genet. 2014, 95(3): 257-274.

34. Alsaadi MM, Erzurumluoglu AM, Rodriguez S, Guthrie PA, Gaunt TR, Omar HZ, et al. Nonsense mutation in coiled-coil domain containing 151 gene (CCDC151) causes primary ciliary dyskinesia. Hum Mutat. 2014, 35(12): 1446-1448.

35. Zhang W, Li D, Wei S, Guo T, Wang J, Luo H, et al. Whole-exome sequencing identifies a novel CCDC151 mutation, c.325G>T (p.E109X), in a patient with primary ciliary dyskinesia and situs inversus. J Hum Genet. 2019, 64(3): 249-252.

36. Mitchison HM, Valente EM. Motile and non-motile cilia in human pathology: from function to phenotypes. J Pathol. 2017, 241(2): 294-309.

37. Bustamante-Marin XM, Ostrowski LE. Cilia and Mucociliary Clearance. Csh Perspect Biol. 2017, 9(4).

38. Chiani F, Orsini T, Gambadoro A, Pasquini M, Putti S, Cirilli M, et al. Functional loss of Ccdc151 leads to hydrocephalus in a mouse model of primary ciliary dyskinesia. Dis Model Mech. 2019, 12(8).

39. Dermokine: An Extensively Differentially Spliced Gene Expressed in Epithelial Cells. J Invest Dermatol. 2007, 127(7): 1622-1631.

40. Leclerc EA, Huchenq A, Kezic S, Serre G, Jonca N. Mice deficient for the epidermal dermokine beta and gamma isoforms display transient cornification defects. J Cell Sci. 2014, 127(Pt 13): 2862-2872.
41. Huang C, Xiang Y, Chen S, Yu H, Wen Z, Ye T, et al. Dermokine contributes to epithelial-mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic cancer. Cancer Sci. 2017, 108(11): 2130-2141.

42. Morris AR, Bos A, Diosdado B, Rooijers K, Elkon R, Bolijn AS, et al. Alternative cleavage and polyadenylation during colorectal cancer development. Clin Cancer Res. 2012, 18(19): 5256-5266.

43. Xiong H, Yang Q, Zhang X, Wang P, Chen F, Liu Y, et al. Significant association of rare variant p.Gly8Ser in cardiac sodium channel beta4-subunit SCN4B with atrial fibrillation. Ann Hum Genet. 2019, 83(4): 239-248.

44. Yang Q, Xiong H, Xu C, Huang Y, Tu X, Wu G, et al. Identification of rare variants in cardiac sodium channel beta4-subunit gene SCN4B associated with ventricular tachycardia. Mol Genet Genomics. 2019, 294(4): 1059-1071.

45. Bigan E, Sasidharan NS, Lejeune FX, Fragnaud H, Parmentier F, Megret L, et al. Genetic cooperativity in multi-layer networks implicates cell survival and senescence in the striatum of Huntington's disease mice synchronous to symptoms. Bioinformatics. 2020, 36(1): 186-196.

46. Bon E, Drifort V, Gradek F, Martinez-Caceres C, Anchelin M, Pelegrin P, et al. SCN4B acts as a metastasis-suppressor gene preventing hyperactivation of cell migration in breast cancer. Nat Commun. 2016, 7: 13648.

47. Marin M, Esteban FJ, Ramirez-Rodrigo H, Ros E, Saez-Lara MJ. An integrative methodology based on protein-protein interaction networks for identification and functional annotation of disease-relevant genes applied to channelopathies. Bmc Bioinformatics. 2019, 20(1): 565.

48. Zhang T, Wu DM, Deng SH, Han R, Liu T, Li J, et al. Integrated Analysis Reveals That Long Non-Coding RNA TUBA4B Can Be Used as a Prognostic Biomarker in Various Cancers. Cell Physiol Biochem. 2018, 49(2): 530-544.

49. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010, 12(4): 351-365.

50. Su YT, Butler M, Zhang M, Zhang W, Song H, Hwang L, et al. MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. Neurooncol Adv. 2020, 2(1): a65.

51. Yang T, Kong Z, Ma W. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. Hum Vaccin Immunother. 2020: 1-8.

52. Alban TJ, Bayik D, Otvos B, Rablj enovic A, Leng L, Jia-Shiun L, et al. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression. Front Immunol. 2020, 11: 1191.

53. Nambirajan A, Malgulwar PB, Sharma A, Boorgula MT, Doddamani R, Singh M, Suri V, Sarkar C, Sharma MC. Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade? Brain Tumor Pathol. 2019, 36(4): 152-161.
54. Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, et al. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol. 2014, 127(5): 731-745.

55. Michealraj KA, Kumar SA, Kim L, Cavalli F, Przelicki D, Wojcik JB, et al. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell. 2020, 181(6): 1329-1345.

56. Filippi I, Carraro F, Naldini A. Interleukin-1beta Affects MDAMB231 Breast Cancer Cell Migration under Hypoxia: Role of HIF-1alpha and NFKappaB Transcription Factors. Mediators Inflamm. 2015, 2015: 789414.

57. Ahn KS, Sethi G, Aggarwal BB. Reversal of chemo-resistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol. 2008, 75(4): 907-913.

Figures

---

Figure 3
GO term, KEGG pathway, and PPI analysis. A, The significant GO terms and KEGG pathway of the Hyper-LGs. B, The significant modules of Hyper-LGs through PPI network analysis. C, The significant GO terms and KEGG pathway of the Hypo-HGs. D, The significant modules of Hypo-HGs through PPI network analysis.

Figure 5
Identification of EPN-PF-related hub DMGs. A, The Venn diagram shows 5 Hyper-LGs by comparing the EPN-PF-related DMGs and the hub genes in WGCNA that were identified as EPN-PF-related hub DMGs. B-F, The relative expression levels of ATP4B (P=7.42E-08), CCDC151 (P=8.791E-07), DMKN (P=1.198E-05), SCN4B (P=5.904E-06), and TUBA4B (P=8.42E-08) were significantly decreased in EPN-PFA cases compared with EPN-PFB cases. G, The volcano plot for EPN-PF related hub DMGs between two subtypes of EPN-PF.
Functional enrichment analysis. A, Landscape evaluation of 28 TME cell infiltration in two subtypes of EPN-PF samples. B, The relationship between the 5 EPN-PF related hub DMGs and the infiltration of immune cells.

Figure 9

GSVA analysis. A, ATP4B-enriched pathways. B, CCDC151-enriched pathways. C, DMKN-enriched pathways. D, SCN4B-enriched pathways. E, TUBA4B-enriched pathways.